EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A light in the dark—reframing direct oral anticoagulant pharmacokinetics and pharmacodynamics for near-patient decision-making

Joseph R Shaw, Jack Ansell

Journal of Thrombosis and Haemostasis · 2026-08 · 24 (8) · 2726-2731

DOI: 10.1016/j.jtha.2026.05.016 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-08. Verfasst von Joseph R Shaw und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology. Inflammation and Chronic Disease Program, the Ottawa Hospital Research Institute, and The Ottawa Hosp…. Hauptthemen laut MEDLINE: Blood Coagulation, Drug Monitoring, Anticoagulants, Factor Xa Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Direct oral anticoagulant (DOAC) level testing is needed most when decisions cannot wait, including anticoagulation-associated bleeding, urgent surgery, and thrombolysis for acute ischemic stroke. Yet the field remains uncertain about what constitutes a clinically meaningful result. Pharmacokinetic assays estimate drug exposure, whereas functional assays seek to characterize anticoagulant effect; conflating these questions has obscured both research priorities and bedside decision-making. Conventional coagulation assays perform poorly at low DOAC concentrations, where many urgent decisions are made, and widely used thresholds such as 30 or 50 ng/mL are pragmatic, actionable cutoffs rather than biologically anchored thresholds derived from pharmacodynamic dose-response relationships or validated against clinically meaningful outcomes. A growing body of literature also challenges the longstanding characterization of DOACs as having predictable pharmacokinetics. Future research must define how residual drug levels relate to coagulation impairment and, in turn, clinical outcomes such as bleeding. Urgent care requires rapid, analytically reliable near-patient DOAC testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood CoagulationDrug MonitoringAnticoagulantsFactor Xa InhibitorsHumansAdministration, OralBlood Coagulation TestsHemorrhagePoint-of-Care TestingPredictive Value of TestsClinical Decision-MakingAnticoagulation ReversalTreatment OutcomeClinical Relevance

Stichwörter der Autor:innen

anticoagulation reversalapixabanblood coagulation testsdrug monitoringpoint-of-care testingrivaroxaban

Substanzen

AnticoagulantsFactor Xa Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology. Inflammation and Chronic Disease Program, the Ottawa Hospital Research Institute, and The Ottawa Hospital, Ottawa, Ontario, Canada. Electronic address: josshaw@toh.ca.
  • Hofstra Northwell Zucker School of Medicine, Hempstead, New York.

Zitieren

APA

Shaw, J. R., & Ansell, J. (2026). A light in the dark—reframing direct oral anticoagulant pharmacokinetics and pharmacodynamics for near-patient decision-making. Journal of Thrombosis and Haemostasis, 24(8), 2726-2731. https://doi.org/10.1016/j.jtha.2026.05.016

Vancouver

Shaw JR, Ansell J. A light in the dark—reframing direct oral anticoagulant pharmacokinetics and pharmacodynamics for near-patient decision-making. Journal of Thrombosis and Haemostasis. 2026;24(8):2726-2731. doi:10.1016/j.jtha.2026.05.016

BibTeX
@article{Shaw2026,
  author = {Shaw, Joseph R and Ansell, Jack},
  title = {A light in the dark—reframing direct oral anticoagulant pharmacokinetics and pharmacodynamics for near-patient decision-making},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {8},
  pages = {2726--2731},
  doi = {10.1016/j.jtha.2026.05.016}
}
Kostenlos starten →